Nuclear cardio-oncology: From its foundation to its future
- PMID: 30788760
- DOI: 10.1007/s12350-019-01655-6
Nuclear cardio-oncology: From its foundation to its future
Abstract
Cardio-oncology is a growing field focused on the prevention and treatment of cardiovascular disease in oncologic patients. While a major focus of chemotherapy-related cardiac dysfunction has been on left ventricular ejection fraction, oncologic treatment can lead to cardiovascular pathology in a variety of ways. The use of multimodality imaging is essential to the care of these patients, with nuclear cardiology playing an important role. We will review nuclear cardiology's history, its current role, and its promising future in cardio-oncology and the management of these patients.
Keywords: Cardiomyopathy; Diagnostic and prognostic application; Metabolic; Molecular imaging agents; Multimodality.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30. - PubMed
-
- Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-14. - PubMed
-
- Minow RA, Benjamin RS, Lee ET, Gottlieb JA. Adriamycin cardiomyopathy—Risk factors. Cancer 1977;39:1397-402. - PubMed
-
- Raj S, Franco VI, Lipshultz SE. Anthracycline-induced cardiotoxicity: A review of pathophysiology, diagnosis, and treatment. Curr Treat Options Cardiovasc Med 2014;16:315. - PubMed
-
- Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996;125:47-58. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources